Ex-Novartis Diagnostics President Assumes New Roles
This article was originally published in Scrip
Gene Walther, who was previously Novartis' diagnostics president, has been appointed head of NetScientific Plc.'s diagnostics franchise and will become the CEO of the company's portfolio company, Vortex BioSciences – effective Jan. 4, 2016. Walther replaces Vortex BioSciences' interim CEO, Michael Boyce-Jacino, who will leave the company and board of directors at the end of December 2015. Most recently Walther was consultant to the Paul G. Allen Family Foundation. Prior to this he was deputy director, diagnostics for the Bill & Melinda Gates Foundation and he also served as executive chair of GenturaDx's board. Walther spent over a decade at Novartis as president and global head of diagnostics.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.